Significant progress is being made in leveraging machine learning and genomic data to improve disease prediction and treatment personalization. Novel algorithms predict breast cancer incidence risk using biochemical biomarkers, showcasing a departure from traditional demographic-based models. Adaptive Biotechnologies partnered with Flatiron Health to embed minimal residual disease (MRD) testing directly into electronic medical records, streamlining clinical decision-making in blood cancers. Additionally, machine learning guides antibiotic use in pediatric diarrheal disease, underscoring an era of precision prescribing. These advances integrate genomic insights and AI into clinical workflows, facilitating tailored therapies and improved patient outcomes.